Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.45 |
| ▸ | CAMK2D | Q13557 | 9/20 | 0.44 |
| ▸ | ICMT | O60725 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | PRKACG | P22612 | 1/20 | 0.39 |
| ▸ | PRKACB | P22694 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25360637 | 0.73 | MAPT (0.61) | CDC25ACAMK2DICMTHDAC3PIM1 | |
| SCHEMBL25360632 | 0.73 | MAPT (0.61) | CDC25ACAMK2DICMTHDAC3PIM1 | |
| SCHEMBL2805276 | 0.73 | REN (0.54) | CDC25AICMT | |
| SCHEMBL2813360 | 0.70 | CNR2 (0.42) | HDAC3MCL1HTR6CNR1CNR2 | |
| SCHEMBL2465449 | 0.69 | CDC25A (0.68) | CDC25AICMTTERTMCL1HTR6 | |
| SCHEMBL2808561 | 0.69 | SLC22A12 (0.42) | HTR6CNR2 | |
| SCHEMBL21246049 | 0.68 | ICMT (0.61) | CDC25AICMTHDAC3TERTMCL1 | |
| SCHEMBL16259057 | 0.68 | ICMT (0.61) | CDC25ACAMK2DICMTHDAC3PIM1 | |
| SCHEMBL27774879 | 0.68 | CAMK2D (0.43) | CDC25ACAMK2DICMTPIM1HTR6 | |
| SCHEMBL2078403 | 0.68 | CNR2 (0.79) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | CDC25A 2365/4885CAMK2D 1038/4885ICMT 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.